Pharmacology and Pharmaceutical Sciences articles for Denmark

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 44

Article ‘Count’ for Pharmacology and Pharmaceutical Sciences.

Journal Count Share
1 0.18
Chiral Polyproline Enables Functional Stealth for Simultaneous Long Circulation and Endoplasmic Reticulum-Targeted Antigen Presentation 0.18
1 0.06
Lattice-distortion Induced Niobium-based Perovskite Polarization Cascade Regulates Na+/K+ ATPase to Enhance Pyroptosis for Cancer Treatment 0.06
1 0.67
Flippase‐Mediated Hybrid Vesicle Division 0.67
2 1.38
Graph Machine Learning Can Estimate Drug Concentrations in Whole Blood from Forensic Screening Results 0.38
In-Solution Characterization of Biomolecular Interaction Kinetics under Native Conditions 1.00
2 1.44
Click‐Cyclized Cell Penetrating Peptides Containing Hydrophobic Proline Derivatives for Efficient Intracellular Delivery 1.00
New Transferrin Receptor‐Targeting Conjugate Effectively Delivers DNA to Mouse Brain 0.44
1 0.11
Prescribing Cascades Among Older Community-Dwelling Adults: Application of Prescription Sequence Symmetry Analysis to a National Database in Ireland 0.11
1 1.00
Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood : A Nationwide Cohort Study. 1.00
1 1.00
Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial 1.00
1 0.02
Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring 0.02
1 0.57
Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia 0.57
1 0.01
Vitamin C conveys geroprotection on primate ovaries 0.01
1 0.78
A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients with Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial. 0.78
1 1.00
Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. 1.00
1 0.44
Per- and polyfluoroalkyl substances exposure in hexavalent chromium exposed workers and the effects of exposure mixtures on oxidative stress and genomic instability 0.44
2 0.96
Prenatal exposure to heavy metals and the trajectory of autistic traits in childhood 0.06
Impact of prenatal and childhood exposure to pyrethroids and chlorpyrifos on motor skills in 7-year-old children from the Odense Child Cohort 0.90
1 1.00
Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk 1.00
4 4.00
The effects of glucose-dependent insulinotropic polypeptide on net splanchnic blood flow in lean humans 1.00
Distribution of Somatostatin and Its Receptors in the Intestinal Tract in Healthy Patients and Patients with Type 2 Diabetes 1.00
The separate and combined effects of GIP, GLP-1 and GLP-2 on markers of bone turnover in type 2 diabetes 1.00
Effect of Denosumab on Sperm Concentration in Men With Severe Oligospermia: A Randomized Controlled Trial 1.00
1 0.80
Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice 0.80
1 0.75
The Modulatory Role of Positional Isomerism in Diolein on the Structural Features of pH-Responsive 2-Hydroxyoleic Acid Nanocarriers 0.75
1 0.06
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy 0.06
1 0.67
Polypharmacy's Association With Mortality: Confounding From Underlying Morbidity 0.67
1 1.00
Hormonal contraception and lymphoma risk in danish women 15–49 years: a nationwide cohort study 1.00
3 1.04
GLP-1 receptor agonists and risk of suicide or suicide attempts – A nationwide cohort and self-controlled case series study 1.00
A five-year risk prediction model of cardiovascular disease in individuals with bipolar disorder: a nationwide register study from Sweden 0.02
Genome-wide meta-analyses of non-response to antidepressants provide insights into underlying molecular genetics and suggest potential pharmacotherapies 0.02
1 0.96
Polystyrene Nanoplastic Contaminants Denature Human Apolipoprotein A-1 0.96
1 0.10
GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice 0.10
1 0.04
Manufacturing-aware generative models enable petascale synthesis of designed DNA 0.04
2 0.90
Structural dynamics and immunogenicity of the recombinant and outer membrane vesicle-embedded Meningococcal antigen NadA 0.10
MAASTY: a (dis)ordered copolymer for structural determination of human membrane proteins in native nanodiscs 0.80
2 1.01
Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial 0.01
Clinical implementation of an AI-based prediction model for decision support for patients undergoing colorectal cancer surgery 1.00
1 1.00
Leukemia in users of contemporary hormonal contraception: A nationwide registry-based cohort study among premenopausal women in Denmark 1.00
1 0.13
Long term use of proton pump inhibitors and risk of stomach cancer: population based case-control study in five Nordic countries 0.13
3 1.89
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial 0.24
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial 0.90
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study 0.75
1 1.00
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.